Bloomberg News

Novo Nordisk Files for U.S. Approval of Degludec, DegludecPlus

September 29, 2011

Sept. 29 (Bloomberg) -- Novo Nordisk A/S said it has submitted to the U.S. Food and Drug Administration two new drug applications for the approval of ultra-longacting insulin Degludec and the insulin combination analogue DegludecPlus, respectively.

To contact the editor responsible for this story: Christian Wienberg at

We Almost Lost the Nasdaq

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus